February 13, 2018 (SEATTLE, WASH.) — The Center for Infectious Disease Research (CID Research) has been awarded a grant from the National Institute of Allergy and Infectious Diseases, one of the U.S. National Institutes of Health, to take a systems-level approach to the critical problem of tuberculosis (TB) infection, specifically focusing on the progression from infection to disease, and variability of treatment. The research ultimately seeks to catalyze new, transformative interventions, such as diagnostics, drugs and vaccines.

SEATTLE, March 24, 2016---Scientists at the Center for Infectious Disease Research, the largest independent nonprofit in the U.S. focused solely on infectious disease research, and the South African Tuberculosis Vaccine Initiative (SATVI) (University of Cape Town) recently developed an important blood test that can predict whether a latent (asymptomatic) Mycobacterium tuberculosis infection is likely to develop into active tuberculosis disease (TB). These blood biomarkers can predict development of disease by measuring the expression of specific RNAs, which measure gene activity, in the blood. The group’s findings were published in The Lancet, a leading medical journal, and could be developed into a diagnostic for large-scale efforts to screen and preventatively treat the disease.

SEATTLE, October 13, 2015--Scientists at the Center for Infectious Disease Research, the largest independent nonprofit in the U.S. focused solely on infectious disease research, partnered with the Tres Cantos Open Lab Foundation at global pharmaceutical company GlaxoSmithKline to advance critically-needed treatments for Mycobacterium tuberculosis (Mtb). The research conducted through the partnership indicates that antifolates may be a candidate for continued tuberculosis drug discovery.